NCT05884320View on ClinicalTrials.gov

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

July 27, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

GlandSalivary Gland Cancers

Interventions

DRUG

Sacituzumab Govitecan

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05884320 - Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers | Biotech Hunter | Biotech Hunter